文献速递性腺与生殖内分泌糖尿病

健康男性中的维生素D与睾酮:一项随机对照试验

Vitamin D and Testosterone in Healthy Men: A Randomized Controlled Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

这项单中心、双盲、随机、安慰剂对照试验纳入98名基线总睾酮≥10.4 nmol/L且25-羟维生素D<75 nmol/L的健康男性,随机接受维生素D3 20,000 IU/周(n=50)或安慰剂(n=50)治疗12周。维生素D治疗对总睾酮水平无显著影响,但显著降低定量胰岛素敏感性检查指数(QUICKI),Matsuda指数呈下降趋势。

要点

  • 健康中年男性补充维生素D3 20,000 IU/周共12周,未显著改变总睾酮水平。
  • 治疗组QUICKI变化中位数为-0.02(P=0.034),提示胰岛素敏感性显著降低。
  • Matsuda指数变化中位数为-0.9(P=0.051),呈下降趋势但未达统计学显著。

核心结论

  • 维生素D治疗对基线总睾酮正常的健康中年男性的总睾酮水平无影响,但显著降低QUICKI。
  • 需要额外研究探讨维生素D对健康男性总睾酮和胰岛素敏感性的影响。

研究设计与样本

  • Graz维生素D与总睾酮随机对照试验(Graz Vitamin D&TT-RCT)为单中心、双盲、随机、安慰剂对照试验,于2012年12月至2017年1月进行。
  • 研究地点为奥地利格拉茨医科大学内分泌门诊。
  • 98名总睾酮≥10.4 nmol/L且25-羟维生素D<75 nmol/L的健康男性完成研究,随机接受维生素D3 20,000 IU/周(n=50)或安慰剂(n=50)治疗12周。
  • 主要结局为质谱法测定的总睾酮;次要结局包括游离睾酮、性激素结合球蛋白、雌二醇、促卵泡激素、促黄体生成素、游离雄激素指数、代谢特征和体成分。

主要发现

  • 健康男性平均年龄39岁(标准差13岁),平均25-羟维生素D 53.3 nmol/L(标准差18.3 nmol/L),平均总睾酮19.1 nmol/L(标准差5.6 nmol/L)。
  • 未发现对总睾酮的显著治疗效应;治疗组总睾酮变化中位数(四分位距)为0.5 nmol/L(-0.63至0.63 nmol/L;P=0.497)。
  • 治疗组QUICKI变化中位数为-0.02(-0.04至0.01;P=0.034),Matsuda指数变化中位数为-0.9(-3.2至0.8;P=0.051)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要额外研究探讨维生素D对健康男性总睾酮和胰岛素敏感性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Available evidence shows an association of vitamin D with androgen levels in men. However, results from preliminary randomized controlled trials (RCTs) are conflicting. OBJECTIVE: To evaluate whether vitamin D supplementation increases total testosterone (TT) levels in healthy men. DESIGN: The Graz Vitamin D&TT-RCT is a single-center, double-blind, randomized, placebo-controlled trial conducted between December 2012 and January 2017. SETTING: Endocrine outpatient clinic at the Medical University of Graz, Austria. PARTICIPANTS: Ninety-eight healthy men with TT levels ≥10.4 nmol/L and 25-hydroxyvitamin D [25(OH)D] levels <75 nmol/L completed the study. INTERVENTION: Subjects were randomly assigned to receive 20,000 IU/wk of vitamin D3 (n = 50) or placebo (n = 50) for 12 weeks. MAIN OUTCOME MEASURES: Primary outcome was TT measured using mass spectrometry. Secondary outcomes were free testosterone, sex hormone-binding globulin, estradiol, follicle-stimulating hormone, and luteinizing hormone levels; free androgen index; metabolic characteristics; and body composition. RESULTS: In healthy men [mean values ± standard deviation: age, 39 years (±13 years); 25(OH)D level, 53.3 nmol/L (±18.3 nmol/L); TT, 19.1 nmol/L (±5.6 nmol/l)], no significant treatment effect on TT was found; however, there were significant effects on quantitative insulin sensitivity check index (QUICKI) and a trend toward decreased Matsuda index. In the treatment group, median (interquartile range) changes for TT, QUICKI, and Matsuda index were 0.5 nmol/L (-0.63 to 0.63 nmol/L; P = 0.497), -0.02 (-0.04 to 0.01; P = 0.034), and -0.9 (-3.2 to 0.8; P = 0.051), respectively. CONCLUSION: Vitamin D treatment had no effect on TT levels in middle-aged healthy men with normal baseline TT, but it significantly decreased QUICKI. Additional studies investigating vitamin D effects on TT and insulin sensitivity in healthy men are required.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lerchbaum E, Pilz S, Trummer C, et al. Vitamin D and Testosterone in Healthy Men: A Randomized Controlled Trial. J Clin Endocrinol Metab. 2017. PMID: 28938446. doi:10.1210/jc.2017-01428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。